Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

SARS-CoV-2 variants resistant to monoclonal antibodies in immunocompromised patients constitute a public health concern
Arturo Casadevall, Daniele Focosi
Journal of Clinical Investigation (2023) Vol. 133, Iss. 6
Open Access | Times Cited: 31

Showing 1-25 of 31 citing articles:

Analysis of SARS-CoV-2 mutations associated with resistance to therapeutic monoclonal antibodies that emerge after treatment
Daniele Focosi, Scott A. McConnell, David J. Sullivan, et al.
Drug Resistance Updates (2023) Vol. 71, pp. 100991-100991
Open Access | Times Cited: 30
An update on the anti-spike monoclonal antibody pipeline for SARS-CoV-2
Daniele Focosi, Massimo Franchini, Arturo Casadevall, et al.
Clinical Microbiology and Infection (2024) Vol. 30, Iss. 8, pp. 999-1006
Closed Access | Times Cited: 9
Intravenous immunoglobulin therapy for COVID-19 in immunocompromised patients: A retrospective cohort study
Remigius Gröning, J Walde, Clas Ahlm, et al.
International Journal of Infectious Diseases (2024) Vol. 144, pp. 107046-107046
Open Access | Times Cited: 7
Next-generation treatments: Immunotherapy and advanced therapies for COVID-19
Jenny Andrea Arévalo-Romero, Sandra M. Chingaté-López, Bernardo Camacho, et al.
Heliyon (2024) Vol. 10, Iss. 5, pp. e26423-e26423
Open Access | Times Cited: 6
Comprehensive Overview of Broadly Neutralizing Antibodies against SARS-COV-2 Variants
Lingyan Cui, Tingting Li, Wenhui Xue, et al.
(2024)
Open Access | Times Cited: 5
Comprehensive Overview of Broadly Neutralizing Antibodies against SARS-CoV-2 Variants
Lingyan Cui, Tingting Li, Wenhui Xue, et al.
Viruses (2024) Vol. 16, Iss. 6, pp. 900-900
Open Access | Times Cited: 4
High-titer convalescent plasma plus nirmatrelvir/ritonavir treatment for non-resolving COVID-19 in six immunocompromised patients
Sammy Huygens, Arvind Gharbharan, Yasmina Serroukh, et al.
Journal of Antimicrobial Chemotherapy (2023) Vol. 78, Iss. 7, pp. 1644-1648
Open Access | Times Cited: 13
Standing the test of COVID-19: charting the new frontiers of medicine
Simon Cauchemez, Giulio Cossu, Nathalie M. Delzenne, et al.
Frontiers in Science (2024) Vol. 2
Open Access | Times Cited: 3
Potent and broadly neutralizing antibodies against sarbecoviruses elicited by single ancestral SARS-CoV-2 infection
Lei Yu, Yajie Wang, Yuanchen Liu, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 3
Susceptibility to SARS-CoV-2 Infection and Immune Responses to COVID-19 Vaccination Among Recipients of Solid Organ Transplants
Vijay Subramanian
The Journal of Infectious Diseases (2023) Vol. 228, Iss. Supplement_1, pp. S34-S45
Open Access | Times Cited: 6
Respiratory delivery of passive immunotherapies for SARS-CoV-2 prophylaxis and therapy
Daniele Focosi, Fabrizio Maggi
Human Vaccines & Immunotherapeutics (2023) Vol. 19, Iss. 2
Open Access | Times Cited: 6
Recommendations on the use of COVID-19 Convalescent Plasma to Treat Immunocompromised Patients
Massimo Franchini, Arturo Casadevall, Jonathon W. Senefeld, et al.
Seminars in Thrombosis and Hemostasis (2023) Vol. 50, Iss. 04, pp. 648-653
Closed Access | Times Cited: 6
Status and Developing Strategies for Neutralizing Monoclonal Antibody Therapy in the Omicron Era of COVID-19
Zuning Ren, Chenguang Shen, Jie Peng
Viruses (2023) Vol. 15, Iss. 6, pp. 1297-1297
Open Access | Times Cited: 5
Broadly potent anti-SARS-CoV-2 antibody shares 93% of epitope with ACE2 and provides full protection in monkeys
Craig Fenwick, Priscilla Turelli, Yoan Duhoo, et al.
Journal of Infection (2023) Vol. 87, Iss. 6, pp. 524-537
Open Access | Times Cited: 5
Functional diversification of innate and inflammatory immune responses mediated by antibody fragment crystallizable activities against SARS-CoV-2
Martina Severa, Marilena P. Etna, Emanuele Andreano, et al.
iScience (2024) Vol. 27, Iss. 5, pp. 109703-109703
Open Access | Times Cited: 1
Considerations for the development of monoclonal antibodies to address new viral variants in COVID-19
Arturo Casadevall, Scott A. McConnell, Daniele Focosi
Expert Opinion on Biological Therapy (2024) Vol. 24, Iss. 8, pp. 787-797
Closed Access | Times Cited: 1
Monoclonal Antibody Therapies Against SARS-CoV-2: Promises and Realities
Daniele Focosi
Current topics in microbiology and immunology (2024)
Closed Access | Times Cited: 1
Analysis of SARS-CoV-2 mutations associated with resistance to therapeutic monoclonal antibodies that emerge after treatment
Daniele Focosi, Scott A. McConnell, David J. Sullivan, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 4
Acetate-encapsulated Linolenic Acid Liposomes Reduce SARS-CoV-2 and RSV Infection
Andrew R. McGill, Eleni Markoutsa, Karthick Mayilsamy, et al.
Viruses (2023) Vol. 15, Iss. 7, pp. 1429-1429
Open Access | Times Cited: 4
Deep learning-guided selection of antibody therapies with enhanced resistance to current and prospective SARS-CoV-2 Omicron variants
Lester Frei, Beichen Gao, Jiami Han, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 4
Prevalence of SARS-CoV-2 Omicron Sublineages and Spike Protein Mutations Conferring Resistance against Monoclonal Antibodies in a Swedish Cohort during 2022–2023
Jonathan Haars, Navaneethan Palanisamy, Frans Wallin, et al.
Microorganisms (2023) Vol. 11, Iss. 10, pp. 2417-2417
Open Access | Times Cited: 3
Engineering immunosuppressive drug-resistant armored (IDRA) SARS-CoV-2 T cells for cell therapy
Qi Chen, Adeline Chia, Shou Kit Hang, et al.
Cellular and Molecular Immunology (2023) Vol. 20, Iss. 11, pp. 1300-1312
Open Access | Times Cited: 2
Anti-SARS-CoV-2 glyco-humanized polyclonal antibody XAV-19: phase II/III randomized placebo-controlled trial shows acceleration to recovery for mild to moderate patients with COVID-19
Garyphallia Poulakou, Pierre‐Joseph Royer, Nikolay Evgeniev, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access
A Robust SARS-CoV-2-specific T and B Cell Response is Associated with Early Viral Clearance in SARS-CoV-2 Omicron-Infected Immunocompromised Individuals
Magda Vergouwe, Jason J. Biemond, Karlijn van der Straten, et al.
The Journal of Infectious Diseases (2024)
Open Access
Monoclonal Antibody Therapies for Infectious Diseases
Arturo Casadevall, Nigel Paneth
Current topics in microbiology and immunology (2024)
Closed Access
Page 1 - Next Page

Scroll to top